Key Points
- Insider sale: Zhenyu Xu sold 4,000 SOPHiA GENETICS shares at an average price of $7.18, worth $28,720, under a pre-arranged Rule 10b5-1 plan. Xu retained 541,493 shares after the transaction.
- Stock and financial performance: SOPH opened at $7.06, with a market capitalization of approximately $592 million and a 12-month trading range of $3.75 to $8.98. The company recently missed quarterly earnings estimates, posting an EPS loss of $0.26, though revenue exceeded expectations.
- Analyst outlook: Wall Street’s consensus rating is Hold, with an average price target of $10.00. Ratings are mixed, ranging from Buy to Sell, while institutional investors own 31.59% of the company.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 4,000 shares of the stock in a transaction that occurred on Tuesday, October 13th. The stock was sold at an average price of $7.18, for a total value of $28,720.00. Following the completion of the transaction, the insider directly owned 541,493 shares of the company's stock, valued at $3,887,919.74. This represents a 0.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Zhenyu Xu also recently made the following trade(s):
- On Monday, October 5th, Zhenyu Xu sold 7,394 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.12, for a total transaction of $60,039.28.
- On Thursday, August 27th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.91, for a total transaction of $89,100.00.
- On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $30,080.00.
- On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total value of $123,930.00.
- On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total transaction of $21,000.00.
- On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total value of $69,200.00.
SOPHiA GENETICS Stock Performance
Shares of SOPH opened at $7.06 on Thursday. The company has a market cap of $592.26 million, a price-to-earnings ratio of -6.14 and a beta of 0.95. The business's fifty day simple moving average is $7.97 and its two-hundred day simple moving average is $6.22. SOPHiA GENETICS SA has a 12 month low of $3.75 and a 12 month high of $8.98. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The business had revenue of $23.31 million during the quarter, compared to analysts' expectations of $21.72 million. Research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
SOPH has been the topic of several research reports. BTIG Research raised their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. HC Wainwright reaffirmed a "buy" rating and set a $14.00 price target on shares of SOPHiA GENETICS in a research report on Monday. Finally, Zacks Research raised shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $10.00.
View Our Latest Research Report on SOPH
Hedge Funds Weigh In On SOPHiA GENETICS
A number of institutional investors have recently bought and sold shares of the stock. AWM Investment Company Inc. purchased a new position in SOPHiA GENETICS during the second quarter valued at $9,809,000. Principal Financial Group Inc. grew its holdings in SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after purchasing an additional 9,800 shares during the period. Hodges Capital Management Inc. bought a new stake in SOPHiA GENETICS during the first quarter valued at about $2,157,000. Sei Investments Co. purchased a new stake in SOPHiA GENETICS in the first quarter worth about $1,772,000. Finally, 1492 Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 8.4% during the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company's stock valued at $1,117,000 after buying an additional 17,406 shares in the last quarter. 31.59% of the stock is owned by institutional investors.
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.
The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
